In this editorial review I summarise the arguments of the main players and websites contributing to a recent debate in these columns on the role of hydroxychloroquine in the treatment of the SARS-CoV-2 pandemic. This exercise has led me to conclude more favourably for hydroxychloroquine.
The authors criticise the primacy of randomised controlled trials (RCT) in the provision of medical knowledge and argue for wider use of alternative study designs on the basis of their “Totality of Evidence-Based Medicine Qualitative Wheel”.
We review the available evidence supporting the use of hydroxychloroquine-based multidrug protocols in the treatment of COVID-19, in response to a recently published editorial in the Tasman Medical Journal.
This is a case report of an Australian aboriginal patient from a remote region who had scabies with secondary discoid lupus erythematosus and dermatopathic lymphadenitis. Both the medical and social issues involved are discussed.
I respond to a recently-published TMJ Editorial Review,1 which commented on an article of mine entitled “The Curious Case of Hydroxychloroquine” published in Quadrant magazine (March 2024).2 I disagree with the reviewer’s points of view for the reasons presented here.
The editor of TMJ responds to a recent article in Quadrant promoting hydroxychloroquine in early COVID-19 infection. Review of the evidence does not support the use of hydroxychloroquine in this indication.
This paper describes the development and performance of an electronic data gathering system for intra-hospital ICU “Outreach” activity, and compares it with the paper-based system it displaced.
This article is a personal case report on the treatment of type 1 diabetes.
This is not a paediatric Journal but we have an interest in all areas of medical practice and its social consequences. The committal of a
Receive the Latest Tasman Medical Journal articles as they are published.
Subscription is free
Find out how to publish your work in the Tasman Medical Journal.
